Dr. Matthew Frank, PhD, MD
Claim this profileStanford University
Area of expertise
Non-Hodgkin's Lymphoma
Matthew Frank, PhD, MD has run 5 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:
Mixed-Cell Lymphoma
Matthew Frank, PhD, MD has run 4 trials for Mixed-Cell Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Stanford University
Stanford Cancer Center
Clinical Trials Matthew Frank, PhD, MD is currently running
CAR T Cells
for Lymphoma
This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion.
Recruiting
1 award
Phase 1
Axicabtagene Ciloleucel
for Non-Hodgkin Lymphoma
This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.
Recruiting
1 award
Phase 1
More about Matthew Frank, PhD, MD
Clinical Trial Related
1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Matthew Frank, PhD, MD has experience with
- Cyclophosphamide
- CD22 CAR
- Fludarabine
- CD22CART
- Biostrap Arm Band
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells
Breakdown of trials Matthew Frank, PhD, MD has run
Non-Hodgkin's Lymphoma
Mixed-Cell Lymphoma
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Frank, PhD, MD specialize in?
Matthew Frank, PhD, MD focuses on Non-Hodgkin's Lymphoma and Mixed-Cell Lymphoma. In particular, much of their work with Non-Hodgkin's Lymphoma has involved Philadelphia Chromosome positive patients, or patients who are CD22 positive.
Is Matthew Frank, PhD, MD currently recruiting for clinical trials?
Yes, Matthew Frank, PhD, MD is currently recruiting for 3 clinical trials in Palo Alto California. If you're interested in participating, you should apply.
Are there any treatments that Matthew Frank, PhD, MD has studied deeply?
Yes, Matthew Frank, PhD, MD has studied treatments such as Cyclophosphamide, CD22 CAR, Fludarabine.
What is the best way to schedule an appointment with Matthew Frank, PhD, MD?
Apply for one of the trials that Matthew Frank, PhD, MD is conducting.
What is the office address of Matthew Frank, PhD, MD?
The office of Matthew Frank, PhD, MD is located at: Stanford University, Palo Alto, California 94305 United States. This is the address for their practice at the Stanford University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.